Radiation Therapy through Genetic Profiling: A Conceptual Framework for Radiogenomic Risk Stratification and Normal-Tissue Radioprotection

Abstract

Radiation therapy remains a central modality in cancer treatment, but normal-tissue toxicity and long-term stochastic effects vary substantially among patients. This conceptual review examines how genetic profiling and radiogenomic risk stratification may support more individualized radiotherapy planning. The paper synthesizes mechanisms of radiation-induced DNA damage, DNA repair, oxidative stress, hypoxia, inflammation, and inherited radiosensitivity, then proposes a clinically cautious framework for incorporating these data into treatment decisions. Particular attention is given to investigational strategies such as transient modulation of DNA repair pathways, plasmid or episomal expression systems, and recombinant viral delivery of radioprotective genes. These approaches are presented as future research directions rather than current standards of care because broad enhancement of DNA repair may protect tumor cells, preserve genomically unstable cells, or increase unintended long-term risk. A practical translational framework is proposed in which tumor sequencing, germline risk assessment, dosimetry, clinical history, toxicity monitoring, and ethical safeguards are combined into multivariable decision models. The paper concludes that radiogenomics may eventually improve the therapeutic ratio of radiotherapy, but only if candidate biomarkers and gene-modulation strategies are prospectively validated, tissue-specific, equitable, and integrated with established clinical judgment.